X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18) 18
male (16) 16
aged (14) 14
index medicus (13) 13
female (12) 12
hematology (12) 12
middle aged (11) 11
adult (10) 10
aged, 80 and over (9) 9
treatment outcome (8) 8
oncology (7) 7
lenalidomide (6) 6
prognosis (6) 6
myelodysplastic syndromes - genetics (5) 5
myelodysplastic syndromes - therapy (5) 5
retrospective studies (5) 5
thalidomide - analogs & derivatives (5) 5
thalidomide - therapeutic use (5) 5
time factors (5) 5
acute myeloid-leukemia (4) 4
antineoplastic agents - therapeutic use (4) 4
cancer (4) 4
chromosome deletion (4) 4
colony-stimulating factor (4) 4
gfm experience (4) 4
myelodysplastic syndromes - drug therapy (4) 4
recurrence (4) 4
risk factors (4) 4
therapy (4) 4
adolescent (3) 3
chemotherapy (3) 3
chromosomes, human, pair 5 (3) 3
cohort studies (3) 3
disease progression (3) 3
erythrocyte transfusion (3) 3
hematology, oncology and palliative medicine (3) 3
immunology (3) 3
international working group (3) 3
myelodysplastic syndromes (3) 3
patient outcomes (3) 3
quality-of-life (3) 3
research (3) 3
risk (3) 3
survival rate (3) 3
trans-retinoic acid (3) 3
young adult (3) 3
5q deletion (2) 2
acute myeloid leukemia (2) 2
anemia (2) 2
antineoplastic combined chemotherapy protocols (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
azacitidine (2) 2
boronic acids - administration & dosage (2) 2
bortezomib (2) 2
care and treatment (2) 2
cell biology (2) 2
chromosomes, human, pair 5 - genetics (2) 2
classification (2) 2
criteria (2) 2
disease-free survival (2) 2
erythropoiesis stimulating agents (2) 2
erythropoietin - therapeutic use (2) 2
expression (2) 2
france - epidemiology (2) 2
g-csf (2) 2
granulocyte colony-stimulating factor - administration & dosage (2) 2
hematinics - therapeutic use (2) 2
leukemia (2) 2
mds (2) 2
medical research (2) 2
microbiology (2) 2
multiple-myeloma (2) 2
multivariate analysis (2) 2
myelodysplasia (2) 2
myelodysplastic syndrome (2) 2
myelodysplastic syndromes - complications (2) 2
myelodysplastic syndromes - epidemiology (2) 2
oncogene proteins, fusion - genetics (2) 2
oncology, experimental (2) 2
outcome (2) 2
polymerase-chain-reaction (2) 2
pyrazines - administration & dosage (2) 2
survival (2) 2
t (2) 2
thalidomide - adverse effects (2) 2
transplantation (2) 2
5q (1) 1
5q syndrome (1) 1
[sdv.imm]life sciences [q-bio]/immunology (1) 1
abstracting (1) 1
acquired immunodeficiency syndrome - complications (1) 1
acquired immunodeficiency syndrome - drug therapy (1) 1
acute lymphoblastic leukemia (1) 1
acute lymphocytic leukemia (1) 1
acute promyelocytic leukemia (1) 1
acute-leukemia (1) 1
adenine - analogs & derivatives (1) 1
adjuvant treatment (1) 1
adolescents and young adults (1) 1
adults (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 16, pp. 2668 - 2676
Journal Article
Journal Article
memo - Magazine of European Medical Oncology, ISSN 1865-5041, 3/2018, Volume 11, Issue 1, pp. 47 - 53
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 08/2014, Volume 89, Issue 8, pp. 803 - 808
Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia characterized by the presence of bone or extramedullary plasma cell tumors. The treatment of choice... 
DEXAMETHASONE | MULTICENTER | EXTRAMEDULLARY PLASMACYTOMA | PLASMA-CELL LEUKEMIA | BONE | BORTEZOMIB | COMBINATION | HEMATOLOGY | IMMUNODEFICIENCY | RADIATION-THERAPY | Bone Neoplasms - mortality | Multivariate Analysis | Plasmacytoma - drug therapy | Prognosis | Multiple Myeloma - mortality | Humans | Middle Aged | Pyrazines - administration & dosage | Neoplasm Recurrence, Local - drug therapy | Male | Plasmacytoma - pathology | Neoplasm Recurrence, Local - mortality | Bone Neoplasms - pathology | Greece | Neoplasm Recurrence, Local - pathology | Multiple Myeloma - drug therapy | Anthracyclines - administration & dosage | Aged, 80 and over | Adult | Female | Retrospective Studies | Bone Neoplasms - drug therapy | Boronic Acids - administration & dosage | Chemotherapy, Adjuvant | Bone Neoplasms - diagnosis | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Antineoplastic Combined Chemotherapy Protocols | Treatment Outcome | Neoplasm Recurrence, Local - diagnosis | Remission Induction | Disease Progression | Plasmacytoma - diagnosis | Melphalan - administration & dosage | Multiple Myeloma - pathology | Adolescent | Plasmacytoma - mortality | Survival Analysis | Aged | Medical research | Patient outcomes | Multiple myeloma | Adjuvant treatment | Medicine, Experimental | Cancer | Index Medicus
Journal Article
Journal of pediatric hematology/oncology, ISSN 1077-4114, 06/2019, p. 1
Prognostic refinement in Fanconi anemia (FA) is needed, especially when considering allogeneic hematopoietic stem cell transplantation (HCT). We studied 20... 
Journal Article
Blood, ISSN 0006-4971, 01/2008, Volume 111, Issue 2, pp. 574 - 582
Journal Article
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 2006, Volume 2006, Issue 1, pp. 192 - 198
Defined by isolated del 5q and no excess of marrow blasts, the "5q- syndrome" is a specific type of myelodysplastic syndrome (MDS) with particular... 
Thalidomide - adverse effects | Thalidomide - analogs & derivatives | Humans | Myelodysplastic Syndromes - classification | Treatment Outcome | Thalidomide - therapeutic use | Myelodysplastic Syndromes - complications | Myelodysplastic Syndromes - drug therapy | Chromosomes, Human, Pair 5
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 1921 - 1921
Abstract Introduction:Long-term outcome of patients with IPSS low or int 1 (LR) MDS treated by IST with horse or rabbit (hATG or rATG) +/-CsA is not well... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 5610 - 5610
Abstract Introduction: The WHO defined overlapping MDS/MPN group includes two rare entities: BCR-ABL negative aCML and MDS/MPN-U, defined by at least 3 months... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 14, pp. 1591 - 1597
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 95 - 95
Abstract Rational The immunomodulatory drug, Lenalidomide (LEN) has proven to be impressively effective for patients (pts) with myelodysplastic syndromes (MDS)... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2010, Volume 28, Issue 2, pp. e22 - e23
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 4961 - 4961
Abstract Abstract 4961 Background: Platelet increase under azacitidine in patients with myelodysplastic syndrome (MDS) has been acknowledged as an early... 
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 3226 - 3226
Abstract Multiple myeloma (MM) is a disease of the elderly and the median age at diagnosis is 65 to 68 years; MM is rarely diagnosed in patients ≤40 years of... 
Journal Article
Haematologica, ISSN 0390-6078, 06/2010, Volume 95, Issue 6, pp. 892 - 899
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 47, pp. 81926 - 81935
While lenalidomide (LEN) is the standard of care for the lower-risk myelodysplastic syndromes (MDS) patients with deletion 5q, 35% will not respond to or do... 
Lenalidomide | Outcome | Myelodysplasia | DECITABINE | EFFICACY | PHASE-III | RISK | ACUTE MYELOID-LEUKEMIA | AZACITIDINE | CELL BIOLOGY | GFM EXPERIENCE | myelodysplasia | DEL(5Q) | lenalidomide | MUTATIONS | TP53 | outcome
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.